GC027, a new chimeric antigen receptor T-cell therapy manufactured with a proprietary allogeneic platform, TruUCAR, has shown effectiveness in a handful of patients with relapsed/refractory T-cell acute lymphoblastic leukemia, a disease with limited treatment options.

You do not currently have access to this content.